

21. Yldiz BO, Aksoy DY, Harmanci A, et al. Effects of l-thyroxine therapy on circulating leptin and adiponectin levels in subclinical hypothyroidism: a prospective study. *Arch Med Res* 2013; 44: 317–320.
22. Soriguer F, Valdes S, Morcillo S, et al. Thyroid hormone levels predict the change in body weight: a prospective study. *Eur J Clin Invest* 2011; 41: 1202–1209.
23. Ozcelik F, Yuksel C, Arslan E, et al. Relationship between visceral adipose tissue and adiponectin, inflammatory markers and thyroid hormones in obese males with hepatos-teatosis and insulin resistance. *Arch Med Res* 2013; 44: 273–280.
24. Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ receptor. *J Neurochem* 2000; 74: 34–41.
25. O'Carroll AM, Selby TL, Palkovits M, et al. Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. *Biochim Biophys Acta* 2000; 1492: 72–80.
26. Scott IC, Masri B, D'Amico LA, et al. The G protein-coupled receptor agr1b1b regulates early development of myocardial progenitors. *Dev Cell* 2007; 12: 403–413.
27. Zeng XX, Wilm TP, Sepich DS, et al. Apelin and its receptor control heart field formation during zebrafish gastrulation. *Dev Cell* 2007; 12: 391–402.
28. Xie H, Tang SY, Cui RR, et al. Apelin and its receptor are expressed in human osteoblasts. *Regul Pept* 2006; 134: 118–125.
29. Principe A, Melgar-Lesmes P, Fernández-Varo G, et al. The hepatic apelin system: A new therapeutic target for liver disease. *Hepatology* 2008; 48: 1193–1201.
30. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. *Endocrinology* 2005; 146: 1764–1771.
31. Kechyn S, Barnes G, Howard L. Assessing dynamic changes in plasma apelin concentration in response to maximal exercise in man. *Eur Respir J* 2015; 46: PA2316.
32. Lambrecht NW, Yakubov I, Zer C, et al. Transcriptomes of purified gastric ECL and parietal cells: identification of a novel pathway regulating acid secretion. *Physiol Genomics* 2006; 25: 153–165.
33. Sörhede Winzell M, Magnusson C, Ahren B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. *Regul Pept* 2005; 131: 12–17.
34. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. *Endocrinology* 2005; 146: 1764–1771.
35. Yasar HY, Demirpence M, Colak A, et al. Serum irisin and apelin levels and markers of atherosclerosis in patients with subclinical hypothyroidism. *Arch Endocrinol Metab* 2019; 63: 16–21.
36. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. *J Exp Med* 2003; 198: 977–985.
37. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. *Endocrinology* 2007; 148: 4687–4694.
38. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest* 2003; 112: 1821–1830.
39. Gong N, Gao C, Chen X, et al. Adipokine expression and endothelial function in subclinical hypothyroidism rats. *Endocr Connect* 2018; 7: 295–304.
40. Europemp. Anotace. (cit. 2018–09–17) Dostupné z [www: <https://europepmc.org/abstract/med/28872087>](https://europepmc.org/abstract/med/28872087). Li Y, Chang J, Jiang T, et al. Serum level of chemerin and bone mineral density in patients with Graves disease. *J Cent South Univ* 2017; 42(8): e947–e952. Dostupné z DOI: <10.11817/j.issn.1672-7347.2017.08.012>
41. Carter JC, Church FC. Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor- γ and plasminogen activator inhibitor-1. *PPAR Research* 2009: 345320.
42. Wahrenberg H, Wennlund A, Hoffstedt J. Increased adipose tissue secretion of interleukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumour necrosis factor alpha, in Graves' hyperthyroidism. *Eur J Endocrinol* 2002; 146: 607–611.
43. Rosc D, Zastawna E, Drewniak W, et al. Plasminogen activators (tissue type t-PA, urokinase type u-PA) and plasminogen activator inhibitor type 1 (PAI-1) in Graves disease. *Med Sci Monit* 1998; 4: 975–978.
44. Davies PH, Black EG, Sheppard MC, et al. Relation between serum interleukin-6 and thyroid hormone concentrations in 270 hospital in-patients with non-thyroidal illness. *Clin Endocrinol (Oxf)* 1996; 44: 199–205.
45. Bartalena L, Brogioni S, Grasso L, et al. Interleukin-6: a marker of thyroid destructive process? *J Clin Endocrinol Metab*. 1994; 79: 1424–1427.
46. Ambati S, Kim HK, Yang KY, et al. Effects of leptin on apoptosis and adipogenesis in 3T3-L1 adipocytes. *Biochem Pharmacol* 2007; 73: 378–384.
47. Torgerson JS, Carlsson B, Stenlöf F, et al. A low serum leptin level at baseline and a large early decline in leptin predict a large 1-year weight reduction in energy-restricted obese humans. *J Clin Endocrinol Metab* 1999; 84: 4197–4203.
48. Näslund E, Andersson I, Degerblad M, et al. Associations of leptin, insulin resistance and thyroid function with long-term weight loss in dieting obese men. *J Intern Med* 2000; 248: 299–308.
49. Reinehr T, Andler W. Thyroid hormones before and after weight loss in obesity. *Arch Dis Child* 2002; 87: 320–323.
50. Yoshida T, Momotani M, Hayashi M, et al. Serum leptin concentrations in patients with thyroid disorders. *Clin Endocrinol (Oxf)* 1998; 48: 299–302.
51. Nakamura T, Nagasaka S, Ishikawa S, et al. Association of hyperthyroidism with serum leptin levels. *Metabolism* 2000; 49: 1285–1288.
52. Escobar-Morreale HF, Escobar del Rey F, Morreale de Escobar G. Thyroid hormones influence serum leptin concentrations in the rat. *Endocrinology* 1997; 138: 4485–4488.
53. Zabrocka L, Klimek J, Swierczynski J. Evidence that triiodothyronine decreases rat serum leptin concentration by down-regulation of leptin gene expression in white adipose tissue. *Life Sci* 2006; 79: 1114–1120.
54. Mantzoros CS, Ozata M, Negrao AB, et al. Synchronicity of frequently sampled thyrotropin (TSH) and leptin concentrations in healthy adults and leptin-deficient subjects: Evidence for possible partial TSH regulation by leptin in humans. *J Clin Endocrinol Metab* 2001; 86: 3284–3291.
55. Pinkney JH, Goodrick SJ, Katz J, et al. Leptin and the pituitary-thyroid axis: a comparative study in lean, obese, hypothyroid and hyperthyroid subjects. *Clin Endocrinol (Oxf)*. 1998; 49: 583–588.
56. Valcavi R, Zini M, Peino R, et al. Influence of thyroid status on serum immunoreactive leptin levels. *J Clin Endocrinol Metab*. 1997; 82: 1632–1634.
57. Corbetta S, Englaro P, Giambona S, et al. Lack of effects of circulating thyroid hormone levels on serum leptin concentrations. *Eur J Endocrinol* 1997; 137: 659–663.
58. Leonhardt U. Serum leptin levels in hypo- and hyperthyroidism. *Eur J Endocrinol* 1998; 157: 75–79.
59. Soriguer F, Valdes S, Morcillo S, et al. Thyroid hormone levels predict the change in body weight: a prospective study. *Eur J Clin Invest* 2011; 41: 1202–1209.
60. Guzel S, Seven A, Guzel EC, et al. Visfatin, leptin, and TNF- α : Interrelated adipokines in insulin-resistant clinical and subclinical hypothyroidism. *Endocr Res* 2013; 38. Dostupné z DOI: <doi.org/10.3109/07435800.2012.760588>
61. Bétry C, et al. Increased TSH in obesity: Evidence for a BMI-independent association with leptin. *Diabetes Metab* 2015; 41: 248–251.
62. Mazaki-Tovi M, Feuermann Y, Segev G, et al. Increased serum leptin and insulin concentrations in canine hypothyroidism. *Vet J* 2010; 18: 109–114.
63. Macek Jílková Z, Pavelka S, Flachs P, et al. Modulation of type I iodothyronine 5'-deiodinase activity in white adipose tissue by nutrition: possible involvement of leptin. *Physiol Res* 2010; 59: 61–69.
64. Luvizotto RA, Conde SA, Sábio MT, et al. Administration of physiologic levels of triiodothyronine increases leptin expression in calorie-restricted obese rats, but does not influence weight loss. *Metabolism* 2010; 59: 1–6.
65. Journals.Anotace. (cit. 2018–09–17) Dostupné z [www: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0074856>](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0074856). de Oliveira M, Luvizotto A, Olimpio RM, et al. Triiodothyronine increases mRNA and protein leptin levels in short time in 3T3-L1 adipocytes by PI3K pathway activation. *PLoS One* 2013; 8(9). Dostupné z DOI: <doi.org/10.1371/journal.pone.0074856>
66. Eray E, Sari F, Ozdem S, et al. Relationship between thyroid volume and iodine, leptin, and adiponectin in obese women before and after weight loss. *Med Princ Pract* 2011; 20: 43–46.
67. Gao CX, Yang B, Guo Q, et al. High thyroid-stimulating hormone level is associated with the risk of developing atherosclerosis in subclinical hypothyroidism. *Horm Metab Res* 2015; 47: 220–224.
68. Cerit ET, Akturk M, Altinova AE, et al. Evaluation of body composition changes, epicardial adipose tissue, and serum omentin-1 levels in overt hypothyroidism. *Endocrine* 2015; 49: 196–203.
69. Stumvoll M, Häring H. Resistin and adiponectin – of mice and men. *Obesity* 2002; 10: 1197–1199.
70. Nogueiras R, Guailillo O, Caminos JE, et al. Regulation of resistin by gonadal, thyroid hormone, and nutritional status. *Obes Res* 2003; 11: 408–414.
71. Krassas G E, Pontikides N, Loustis K, et al. Resistin levels in hyperthyroid patients before and after restoration of thyroid function: relationship with body weight and body composition. *Eur J Endocrinol* 2005; 153: 217–221.
72. El Gawad SS, El Kenawy F, Mousa AA, et al. Plasma levels of resistin and ghrelin before and after treatment in patients with hyperthyroidism. *Endocr Pract* 2012; 18: 376–381.
73. Krassas GE, Pontikides N, Loustis K, et al. Resistin levels are normal in hypothyroidism and remain unchanged after attainment of euthyroidism: relationship with insulin levels and anthropometric parameters. *J Endocrinol Invest* 2006; 29: 606–612.
74. Ziora KT, Oswiecimska JM, Swietochowska E, et al. Assessment of serum levels resistin in girls with anorexia nervosa. Part II. Relationships between serum levels of resistin and thyroid, adrenal and gonadal hormones. *Neuro Endocrinol Lett* 2011; 32: 697–703.
75. Murphy K, Travers P, Walport M. *Janeway's Immunobiology*. 7th ed. Garland Science: New York (USA) 2008.
76. Díez JJ, Hernanz A, Medina S, et al. Serum concentrations of tumor necrosis factor- α and soluble tumor necrosis factor- α receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. *Clin Endocrinol (Oxf)* 2002; 57: 515–521.
77. Blüher M. Vaspin in obesity and diabetes: pathophysiological and clinical significance. *Endocrine* 2012; 41: 176–182.